Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337309 · ClinicalTrials.gov registry record · Phase 1
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
A Phase 1 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02337309 is a Phase 1 study that was terminated before completion, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 4 participants.
The verdict
NCT02337309, a Phase 1 study, was terminated before completion, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. Funding Source - FDA OOPD
Interventions
- DRUG SF1126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337309
The ClinicalTrials.gov registry entry for NCT02337309 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SF1126 is the first listed.
NCT02337309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02337309 about?
NCT02337309 is a clinical study titled "SF1126 for Patients With Relapsed or Refractory Neuroblastoma". SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation d...
What is the current status of trial NCT02337309?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-07-09. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02337309?
The interventions under investigation include: SF1126 (DRUG).
Who is sponsoring clinical trial NCT02337309?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.